Health Score

0 Good

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 162 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact162 DOIs

Add license metadata to 104 records

License metadata tells indexers and readers how each article may be reused.

Medium impact104 DOIs

Add abstracts to 73 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact73 DOIs

DOIs for this ISSN

Showing the top 5 of 242 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysp… (10.36401/jipo-21-x2)	Abstract ORCID License	110.78	29
2	Being Realistic and Optimistic in Curing Cancer (10.4103/jipo.jipo_20_18)	Abstract ORCID License	102.13	22
3	Clinical Development of Colony-Stimulating Factor 1 Receptor… (10.36401/jipo-20-32)	ORCID License	87.41	55
4	Cancer Immunotherapy for the Immunosuppressed: Dissecting th… (10.4103/jipo.jipo_15_19)	Abstract ORCID License	83.55	12
5	The Impact of Immune Checkpoint Inhibitor-Related Adverse Ev… (10.4103/jipo.jipo_12_18)	ORCID License	81.16	41
6	Extracellular Signal-Regulated Kinase (ERK) Inhibitors in On… (10.4103/jipo.jipo_17_18)	ORCID License	79.55	38
7	Targeted Cancer Therapy and Its Ophthalmic Side Effects: A R… (10.36401/jipo-20-21)	ORCID License	72.36	27
8	COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Fin… (10.36401/jipo-20-x7)	Abstract ORCID License	71.57	8
9	Cardiovascular Complications of Chimeric Antigen Receptor T-… (10.36401/jipo-20-10)	ORCID License	70.75	25
10	Real-World Experiences of CAR T-Cell Therapy for Large B-Cel… (10.36401/jipo-21-2)	ORCID License	68.09	22
11	Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pn… (10.36401/jipo-20-22)	ORCID License	63.94	18
12	The Impact of COVID-19 on Cancer Clinical Trials Conducted b… (10.36401/jipo-20-30)	Abstract ORCID License	63.38	6
13	Wilms' Tumor 1 (WT1): The Vaccine for Cancer (10.36401/jipo-20-12)	ORCID License	62.76	17
14	Reactivation of Hepatitis B Virus Among Patients With Cancer… (10.36401/jipo-20-19)	Abstract ORCID License	58.36	5
15	The Role of the Cervicovaginal and Gut Microbiome in Cervica… (10.36401/jipo-20-17)	ORCID License	57.31	13
16	Pyoderma Gangrenosum Following Initiation of Immune Checkpoi… (10.4103/jipo.jipo_11_18)	ORCID License	57.31	13
17	Rheumatic and Musculoskeletal Adverse Events with Immune Che… (10.4103/jipo.jipo_12_19)	ORCID License	55.70	12
18	Bromodomain and Extra-Terminal (BET) Domain Protein Inhibito… (10.4103/jipo.jipo_2_20)	ORCID License	55.70	12
19	Identification of Genetic Alterations by Circulating Tumor D… (10.36401/jipo-20-3)	ORCID License	53.96	11
20	Pneumocystis Infection in Two Patients Treated with Both Imm… (10.4103/jipo.jipo_23_19)	ORCID License	53.96	11
21	Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in O… (10.36401/jipo-22-1)	ORCID	52.68	127
22	Bronchiolitis Obliterans after Combination Immunotherapy wit… (10.4103/jipo.jipo_8_18)	ORCID License	52.07	10
23	Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK… (10.36401/jipo-20-35)	ORCID License	50.00	9
24	Safety of Immune Checkpoint Blockade in Patients with Cancer… (10.4103/jipo.jipo_11_19)	ORCID License	50.00	9
25	Vedolizumab Achieved Clinical and Histologic Remission in a… (10.4103/jipo.jipo_18_18)	ORCID License	50.00	9
26	Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab… (10.4103/jipo.jipo_7_18)	ORCID License	50.00	9
27	Pneumonitis After Precision Oncology Therapies: A Concise Re… (10.4103/jipo.jipo_9_18)	ORCID License	50.00	9
28	Repurposing Interleukin-6 Inhibitors to Combat COVID-19 (10.36401/jipo-20-11)	ORCID License	47.71	8
29	Cardiotoxicity of FDA-approved immune checkpoint inhibitors:… (10.4103/jipo.jipo_15_18)	ORCID License	47.71	8
30	Impact of COVID-19 on Patients with Cancer Receiving Immune… (10.36401/jipo-20-34)	ORCID License	45.15	7
31	Chronic Myelomonocytic Leukemia: Hematopathology Perspective (10.36401/jipo-21-1)	ORCID License	45.15	7
32	Prognostic Impact of Cytotoxic CD4 T Cells in Tumor Immune M… (10.36401/jipo-21-15)	Abstract ORCID	45.15	7
33	Implementation of a Novel Web-Based Lesion Selection Tool to… (10.36401/jipo-21-5)	ORCID License	45.15	7
34	Cancer Immunotherapy for Immunocompromised Patients: An Ofte… (10.4103/2666-2345.278414)	Abstract ORCID License	45.15	3
35	Immune Checkpoint Blockade in Gastrointestinal Cancers: The… (10.4103/jipo.jipo_1_20)	ORCID License	45.15	7
36	Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus… (10.4103/jipo.jipo_16_19)	ORCID License	45.15	7
37	The Study of Druggable Targets in Nonsquamous Non-Small-Cell… (10.4103/jipo.jipo_22_18)	ORCID License	45.15	7
38	Eosinophilic Fasciitis in a Patient Treated by Atezolizumab… (10.4103/jipo.jipo_8_19)	ORCID License	45.15	7
39	Inflammation in Myeloid Malignancies: From Bench to Bedside (10.36401/jipo-21-3)	ORCID License	42.25	6
40	Personalized Cancer Immunotherapy: Today’s Challenge and Tom… (10.4103/jipo.jipo_13_18)	ORCID License	42.25	6
41	Review of Immunogenomics and the Role of Tumor Mutational Bu… (10.4103/jipo.jipo_19_19)	ORCID License	42.25	6
42	Cancer Epigenomics and Beyond: Advancing the Precision Oncol… (10.36401/jipo-20-18)	ORCID License	38.91	5
43	RS3PE Following Treatment With Combination of Hormonal Thera… (10.36401/jipo-20-2)	ORCID License	38.91	5
44	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors… (10.36401/jipo-20-20)	ORCID License	38.91	5
45	First-Line PARP Inhibitors—Emerging Side Effects Require Cau… (10.36401/jipo-20-33)	ORCID License	38.91	5
46	Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Re… (10.36401/jipo-22-9)	ORCID	38.29	33
47	Highlights on Ocular Toxicity of Immune Checkpoint Inhibitor… (10.36401/jipo-22-14)	ORCID	36.93	29
48	The immune system, cancer, and pathogens: It takes three to… (10.36401/jipo-21-x1)	Abstract ORCID License	35.78	2
49	Synchronized Tissue Acquisition Techniques for Novel Biomark… (10.36401/jipo-21-x3)	Abstract ORCID License	35.78	2
50	Immunotherapy Use in Patients with HIV and Non-Small-Cell Lu… (10.4103/jipo.jipo_13_19)	Abstract ORCID License	35.78	2